---
$id: https://graph.org.ai/products/commodity/51131704
$type: Product
source: UNSPSC
code: "51131704"
title: "Urokinase"
class: "51131700"
classTitle: "Thrombolytic drugs and platelet aggregation inhibitors"
family: "51130000"
familyTitle: "Hematolic drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Urokinase

**UNSPSC Code**: 51131704
**Class**: [Thrombolytic drugs and platelet aggregation inhibitors](Thrombolytic drugs and platelet aggregation inhibitors.mdx)
**Family**: [Hematolic drugs](../Hematolic drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes a plasminogen activator with the molecular formula C1376H2145N383O406S18, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 83G67E21XI, more generally known as urokinase. European Medicines Agency schedules urokinase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05055MIG. The term UROKINASE is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 21 no. 12 1967, list 7. UROKINASE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule urokinase under HS 35079090 and SITC 51691. As of Q4 2014, UROKINASE remains the US FDA Preferred Term for this commodity. SMILES: NONE.

